1-5 of 5
Rafael Sarmiento
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial

Luciano J. Costa, Fredrik Schjesvold, Rakesh Popat, David Siegel, Saad Z. Usmani, Syed Abbas Ali, Michael P. Chu, Monique A. Hartley-Brown, Nizar J. Bahlis, Albert Oriol, Joaquín Martínez Lopez, Enrique M. Ocio, Karthik Ramasamy, Donna Reece, Emma Searle, Allison Gaudy, Antonina Kurtova, Wen Zhang, Rafael Sarmiento, August Dietrich, Jessica Katz, Michael Pourdehnad, Paul G. Richardson
Journal: Blood
Blood (2024) 144 (Supplement 1): 677.
https://doi.org/10.1182/blood-2024-198403
Published: 2024
Journal Articles

First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial

Luciano J. Costa, MD PhD, Sandy W. Wong, Arancha Bermúdez, Javier de la Rubia, María-Victoria Mateos, Enrique M. Ocio, Paula Rodríguez-Otero, Jesús San-Miguel, Shaoyi Li, Rafael Sarmiento, Pilar Lardelli, Allison Gaudy, Isaac Boss, Lisa M. Kelly, Michael R. Burgess, Kristen Hege, William I. Bensinger
Journal: Blood
Blood (2019) 134 (Supplement_1): 143.
https://doi.org/10.1182/blood-2019-122895
Published: 2019
Journal Articles

Avadomide (CC-122), a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Jean-Marie Michot, MD, Reda Bouabdallah, MD, Jeanette K. Doorduijn, MD PhD, Umberto Vitolo, Marie José Kersten, MD PhD, Annalisa Chiappella, MD, Pier Luigi Zinzani, MD, Gilles Salles, MD PhD, Fontanet Bijou, MD, Rafael Sarmiento, Silvia Mosulen, PhD, Cristina Mendez, Shailaja Uttamsingh, PhD, Michael Pourdehnad, MD, Kristen Hege, MD, Li Li, Zariana Nikolova, MD PhD, Vincent Ribrag, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 449.
https://doi.org/10.1182/blood-2018-99-110213
Published: 2018
Journal Articles

CC-122, a Novel Cereblon Modulating Agent, in Combination with Obinutuzumab (GA101) in Patients with Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Jean-Marie Michot, MD, Reda Bouabdallah, MD, Jeanette K. Doorduijn, MD PhD, Umberto Vitolo, MD, Marie José Kersten, MD PhD, Annalisa Chiappella, MD, Pier Luigi Zinzani, MD, Rafael Sarmiento, Silvia Mosulen, PhD, Cristina Mendez, Michael Petrarca, PhD, Michael Pourdehnad, MD, Kristen Hege, MD, Li Li, Zariana Nikolova, MD PhD, Vincent Ribrag, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 411.
https://doi.org/10.1182/blood.V130.Suppl_1.411.411
Published: 2017
Journal Articles

A Phase 1B Study of CC-122 in Combination with Obinutuzumab (GA101) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin Lymphoma

Jean-Marie Michot, MD, Jeanette K Doorduijn, MD PhD, Reda Bouabdallah, MD, Umberto Vitolo, MD, Pier Luigi Zinzani, MD PhD, Marie Jose Kersten, MD PhD, Annalisa Chiappella, MD, Rafael Sarmiento, Marlene Zuraek, MD, Michael Pourdehnad, Kristen Hege, MD, Zariana Nikolova, MD PhD, Vincent Ribrag, MD
Journal: Blood
Blood (2016) 128 (22): 4199.
https://doi.org/10.1182/blood.V128.22.4199.4199
Published: 2016